The DOI matches its Crossref record; 261 of the 263 references it cites were found in a registry or an index.
Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
Open accessAbstract
NAFLD is closely linked with hepatic insulin resistance. Accumulation of hepatic diacylglycerol activates PKC-ε, impairing insulin receptor activation and insulin-stimulated glycogen synthesis. Peripheral insulin resistance indirectly influences hepatic glucose and lipid metabolism by increasing flux of substrates that promote lipogenesis (glucose and fatty acids) and gluconeogenesis (glycerol and fatty acid-derived acetyl-CoA, an allosteric activator of pyruvate carboxylase). Weight loss with diet or bariatric surgery effectively treats NAFLD, but drugs specifically approved for NAFLD are not available. Some new pharmacological strategies act broadly to alter energy balance or influence pathways that contribute to NAFLD (e.g., agonists for PPAR γ, PPAR α/δ, FXR and analogs for FGF-21, and GLP-1). Others specifically inhibit key enzymes involved in lipid synthesis (e.g., mitochondrial pyruvate carrier, acetyl-CoA carboxylase, stearoyl-CoA desaturase, and monoacyl- and diacyl-glycerol transferases). Finally, a novel class of liver-targeted mitochondrial uncoupling agents increases hepatocellular energy expenditure, reversing the metabolic and hepatic complications of NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, in cases of concurrent diabetes and insulin resistance, oxidative stress in other tissues due to hyperglycaemia may compound lipotoxicity in the liver.34”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Mechanisms of fatty acid-induced inhibition of glucose uptake.
Boden, G., Chen, X., Ruiz, J., White, J. V., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117252 · Cited by 3,720
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416 · cited 1×
“A common SNP (rs738409, I148M) in the lipid droplet protein patatin-like phospholipase domain-containing protein 3 (PNLPA3, also called adiponutrin) has been associated with NAFLD and fibrosis (Romeo et al., 2008; Singal et al., 2014).”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Nonetheless, pioglitazone did improve several discrete metrics of hepatic inflammation (Sanyal et al., 2010).”
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,874 · cited 1×
“Perspective These include 3-phosphoinositide-dependent kinase-1 (PDK1) and mechanistic target of rapamycin complex 2 (mTORC2) (Guertin and Sabatini, 2007), which converge on Akt phosphorylation (Alessi et al., 1997; Guertin and Sabatini, 2007; Stephens et al., 1998).”
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · cited 2×
“and mechanistic target of rapamycin complex 2 (mTORC2) (Guertin and Sabatini, 2007), which converge on Akt phosphorylation (Alessi et al.”
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Self-citation
Flagged first, then by citations
2 of the 263 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“Othermetabolic causes of NAFLD andNASH, which are most often genetically related, include (1) defects in intrahepatic lipolysis (e.g., decreased ATGL/CGI-58 activity); (2) defects in triglyceride export (e.g., defective Apo-B 100, MTTP activity); (3) increased glucokinase activity, resulting in increased hepatic DNL;…”
BackgroundInfluentialSelf-citationRole of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease
Chen, Z., Tian, R., She, Z., Cai, J., & Li, H. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.02.025 · Cited by 1,340
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Stefan, N., Häring, H., & Cusi, K. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 874
Mitochondria as a therapeutic target for common pathologies
Murphy, M. P., & Hartley, R. C. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.174 · Cited by 846
Casares, D., Escribá, P. V., & Rosselló, C. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092167 · Cited by 863
“In fat metabolism, the liver cells break down fats and produce energy (reviewed in [162]).”
BackgroundXiong, X., Kuang, H., Ansari, S., Liu, T., Gong, J., Wang, S., Zhao, X.-Y., Ji, Y., Li, C., Guo, L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.028 · Cited by 784
AMP-activated protein kinase: the current landscape for drug development
Steinberg, G. R., & Carling, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0019-2 · Cited by 785
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 692
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Tilg, H., Adolph, T. E., Dudek, M., & Knolle, P. A. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00501-9 · Cited by 539
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 520
The cell biology of systemic insulin function
Tokarz, V. L., MacDonald, P. E., & Klip, A. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201802095 · Cited by 471
“This ensures that a portion of dietary glucose is effectively stored in the liver and is only released to the rest of the body upon cessation of insulin action (between meals) or upon metabolic demand enacted by other “counterregulatory” hormones (Samuel and Shulman, 2018).”
BackgroundMantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., Schattenberg, J. M., Tilg, H., Byrne, C. D., & Targher, G. (2022) · Gut · doi:10.1136/gutjnl-2020-323082 · Cited by 402
Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo
Feyter, H. M. D., Behar, K. L., Corbin, Z. A., Fulbright, R. K., Brown, P. B., McIntyre, S., Nixon, T. W., Rothman, D. L., & de Graaf, R. A. (2018) · Science Advances · doi:10.1126/sciadv.aat7314 · Cited by 378
“(D) 2H NMR spectra from selected locations depicted in the T2W MR image, including tissue (1 and 3) within the lesion as seen on T1W CE, (2) from normal-appearing occipital lobe, and (4) containing cerebrospinal fluid from the left lateral ventricle.”
BackgroundXu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 387
“of a profibrotic environment appear to be promising therapeutic strategies.(71,72) Here we review some of the most promising therapeutic targets for NASH, and describe compounds being evaluated against these targets in clinical or preclinical stages (Tables 1 and 2).”
BackgroundWhite, P. J., McGarrah, R. W., Grimsrud, P. A., Tso, S.-C., Yang, W.-H., Haldeman, J. M., Grenier-Larouche, T., An, J., Lapworth, A. L., Astapova, I., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.04.015 · Cited by 365
“We also observed improved glucose tolerance in response to those maneuvers, possibly secondary to the marked lowering of hepatic TG content (Samuel and Shulman, 2017).”
Rao, Y., Kuang, Z., Li, C., Guo, S., Xu, Y., Zhao, D., Hu, Y., Song, B., Jiang, Z., Ge, Z., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1927633 · Cited by 356
“Diacylglycerol (DAG) is a representative intermediate of lipid metabolism that induces activation of oxidative stress and displays toxicity to hepatocytes, leading to apoptosis and liver injury in vivo.(26) Notably, treatment with A.”
BackgroundAn integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD
Garcia, D., Hellberg, K., Chaix, A., Wallace, M., Herzig, S., Badur, M. G., Lin, T. C., Shokhirev, M. N., Pinto, A. F. M., Ross, D. S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.036 · Cited by 296
“In the liver, PKCε is the isoform most strongly associated with lipid-induced hepatic insulin resistance (Samuel and Shulman, 2018).”
BackgroundInfluentialPharmacotherapy for NASH: Current and emerging
Konerman, M. A., Jones, J. C., & Harrison, S. A. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.015 · Cited by 297
“Journal of storage via stimulation of lipogenesis and inhibition of lipid oxidation.(63) Mouse models of ACC inhibitors have shown that these agents can reduce liver triglycerides, but were also noted to increase plasma triglycerides.”
Metabolic and Signaling Roles of Ketone Bodies in Health and Disease
Puchalska, P., & Crawford, P. A. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-111120-111518 · Cited by 304
Dietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294
Yang, H., Yang, T., Cai, H., Zhou, Y., Jiang, Z., Qian, X., Du, L., Mao, S., Yin, X., & Lü, Q. (2019) · Phytotherapy Research · doi:10.1002/ptr.6486 · Cited by 281
“A growing evidence supports the same pathogenesis in the development and progression of T2DM and NAFLD, including hyperglycemia, oxidative stress, cellular inflammatory factors, and insulin resistance (Gao & Tsukamoto, 2016; Haas, Francque, & Staels, 2016; Samuel & Shulman, 2018).”
BackgroundLuukkonen, P. K., Dufour, S., Lyu, K., Zhang, X., Hakkarainen, A., Lehtimäki, T. E., Cline, G. W., Petersen, K. F., Shulman, G. I., & Yki‐Järvinen, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922344117 · Cited by 261
“The marked fall in IHTG is also likely to underrepresent a considerable fall in intrahepatocellular diacylglycerol content, a key mediator of hepatic insulin resistance (1, 45), under conditions of reduced net re-esterification.”
BackgroundSelf-citationDela Cruz, C. S., & Kang, M.-J. (2018) · Mitochondrion · doi:10.1016/j.mito.2017.12.001 · Cited by 255
“Although the underlying pathophysiologic mechanism that contribute to the development and progression of NAFLD and NASH are complex (Samuel and Shulman, 2017), the activation of the innate immune system in association with chronic inflammation has been highlighted as an important feature of its pathogenesis (Arrese et…”
The circadian clock and liver function in health and disease
Mukherji, A., Bailey, S. M., Staels, B., & Baumert, T. F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.020 · Cited by 246
“generally initiated by perturbations in free fatty acid (FFA) metabolism, which drives excessive TG accumulation in hepatocytes ((36-37)).”
BackgroundInfluentialmiRNAs and NAFLD: from pathophysiology to therapy
Gjorgjieva, M., Sobolewski, C., Dolicka, D., de Sousa, M. C., & Foti, M. (2019) · Gut · doi:10.1136/gutjnl-2018-318146 · Cited by 220
Rosqvist, F., Kullberg, J., Ståhlman, M., Cedernaes, J., Heurling, K., Johansson, H.-E., Iggman, D., Wilking, H., Larsson, A. O., Eriksson, O., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00160 · Cited by 246
Ratziu, V., de Guevara, L., Safadi, R., Poordad, F., Fuster, F., Flores-Figueroa, J., Arrese, M., Fracanzani, A. L., Ben Bashat, D., Lackner, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01495-3 · Cited by 222
Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Parola, M., & Pinzani, M. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101231 · Cited by 239
Rosso, C., Kazankov, K., Younes, R., Esmaili, S., Marietti, M., Sacco, M., Carli, F., Gaggini, M., Salomone, F., Møller, H. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.031 · Cited by 217
Intestinal Barrier and Permeability in Health, Obesity and NAFLD
Portincasa, P., Bonfrate, L., Khalil, M., Angelis, M. D., Calabrese, F. M., D’Amato, M., Wang, D. Q. ‐., & Ciaula, A. D. (2021) · Biomedicines · doi:10.3390/biomedicines10010083 · Cited by 219
“According to a recent debate, the term “non-alcoholic” seems to overemphasize “alcohol” rather than metabolic risk factors [306,346].”
BackgroundZhao, W., Bian, Y., Wang, Q., Yin, F., Yin, L., Zhang, Y.-L., & Liu, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00681-w · Cited by 212
“Therefore, one approach to treat NAFLD is to reduce the endogenous production of fatty acids in the liver by inhibiting de novo lipogenesis [48, 49].”
BackgroundInhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia
Morrow, M. R., Batchuluun, B., Wu, J., Ahmadi, E., Leroux, J. M., Mohammadi-Shemirani, P., Desjardins, E. M., Wang, Z., Tsakiridis, E. E., Lavoie, D. C. T., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.004 · Cited by 199
Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update
Barchetta, I., Cimini, F. A., & Cavallo, M. G. (2020) · Nutrients · doi:10.3390/nu12113302 · Cited by 198
“As a vicious circle, once MAFLD is established it increases the hepatic insulin resistance, which, in turn, may trigger, in 30–40% of cases, MAFLD evolution towards steatohepatitis (NASH), and eventually, cirrhosis, liver failure, and hepatocarcinoma [4,5].”
BackgroundLuci, C., Bourinet, M., Leclère, P. S., Anty, R., & Gual, P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597648 · Cited by 195
“Weight gain, insulin resistance, type 2 diabetes mellitus, and hypertension are risk factors for NAFLD progression (6, 7).”
BackgroundA Membrane-Bound Diacylglycerol Species Induces PKCϵ-Mediated Hepatic Insulin Resistance
Lyu, K., Zhang, Y., Zhang, D., Kahn, M., ter Horst, K. W., Rodrigues, M. R. D. S., Gaspar, R. C., Hirabara, S. M., Luukkonen, P. K., Lee, S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.001 · Cited by 173
“DAGs, the penultimate intermediate in triglyceride synthesis, have been shown to be highly associated with hepatic steatosis and HIR in both rodents and humans (Abulizi et al., 2017; Kumashiro et al., 2011; Luukkonen et al., 2016; Magkos et al., 2012; Perry et al., 2015b; Samuel and Shulman, 2018; Ter Horst et al., 20…”
BackgroundSelf-citationInsights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
Yu, Y., Cai, J., She, Z., & Li, H. (2018) · Advanced Science · doi:10.1002/advs.201801585 · Cited by 166
Ciaula, A. D., Baj, J., Garruti, G., Celano, G., Angelis, M. D., Wang, H. H., Palo, D. M. D., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082648 · Cited by 166
“Ingested glucose is re-directed to the liver during insulin resistant status [47] and glucose is primarily processed to FA via DNL [46,52].”
BackgroundAlkhouri, N., Lawitz, E., Noureddin, M., DeFronzo, R., & Shulman, G. I. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1668374 · Cited by 162
“potent anti-steatotic action and beneficial effects on lipids and cardiovascular outcomes may prove to be more efficacious than GS-0976 [23].”
BackgroundSelf-citationMitogen-Activated Protein Kinase Regulation in Hepatic Metabolism
Lawan, A., & Bennett, A. M. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.10.007 · Cited by 166
Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis
Zhao, X.-Y., Xiong, X., Liu, T., Mi, L., Peng, X., Rui, C., Guo, L., Li, S., Li, X., & Lin, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-05383-2 · Cited by 160
Hippo Signaling: Key Emerging Pathway in Cellular and Whole-Body Metabolism
Ardestani, A. D., Lupše, B., & Maedler, K. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.04.006 · Cited by 161
He, F., Huang, Y., Song, Z. Q., Zhou, H. J., Zhang, H., Perry, R. J., Shulman, G. I., & Wang, M. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20201416 · Cited by 160
Self-citationPlasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease
Henderson, G. C. (2021) · Nutrients · doi:10.3390/nu13082590 · Cited by 152
“Elevated DAG can lead to IR though activation of specific protein kinase C isoforms [28,32,33].”
BackgroundXu, H., Du, X., Xu, J., Zhang, Y., Tian, Y., Liu, G., Wang, X., Ma, M., Du, W., Liu, Y., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000603 · Cited by 149
“such as cardiovascular complications and certain cancers, leading to a consequent increase in mortality, morbidity, and economic burden [3].”
BackgroundStructural basis for FGF hormone signalling
Chen, L., Fu, L., Sun, J., Huang, Z., Fang, M., Zinkle, A., Liu, X., Lu, J., Pan, Z., Wang, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06155-9 · Cited by 147
Glucocorticoid-Induced Fatty Liver Disease
Rahimi, L., Rajpal, A., & Ismail‐Beigi, F. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s247379 · Cited by 151
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Syed‐Abdul, M. M. (2023) · Metabolites · doi:10.3390/metabo14010012 · Cited by 166
Reproductive Endocrinology of Nonalcoholic Fatty Liver Disease
Grossmann, M., Wierman, M. E., Angus, P., & Handelsman, D. J. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00158 · Cited by 146
Endocrine role of bone in the regulation of energy metabolism
Zhou, R., Guo, Q., Xiao, Y., Guo, Q., Huang, Y., Li, C., & Luo, X. (2021) · Bone Research · doi:10.1038/s41413-021-00142-4 · Cited by 157
Barbier‐Torres, L., Fortner, K. A., Iruzubieta, P., Delgado, T. C., Giddings, E. L., Chen, Y., Champagne, D., Fernández‐Ramos, D., Mestre, D., Gómez‐Santos, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16991-2 · Cited by 147
Portincasa, P., Khalil, M., Mahdi, L., Perniola, V., Idone, V., Graziani, A., Baffy, G., & Ciaula, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115640 · Cited by 167
“…individuals with MASLD should be managed by improving the systemic metabolic homeostasis [198], dysregulation of glucose and lipid metabolism [82], and eventually correct the involvement of skeletal muscle (i.e., myosteatosis, sarcopenia, and release of myokines) [199,200], of intestinal…”
BackgroundInfluentialHepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity
Régnier, M., Polizzi, A., Smati, S., Lukowicz, C., Fougerat, A., Lippi, Y., Fouché, E., Lasserre, F., Naylies, C., Bétoulières, C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63579-3 · Cited by 149
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
Ciaula, A. D., Passarella, S., Shanmugam, H., Noviello, M., Bonfrate, L., Wang, D. Q. ‐., & Portincasa, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105375 · Cited by 142
“In lipid synthesis, FFA in the hepatocyte cytosol is esterified with glycerol to form TG via the key enzymes, diglyceride acyltransferase (DGAT)1 and DGAT2, and exported to blood as very-low-density lipoprotein (VLDL) [38].”
BackgroundHepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
“Intrahepatic content of DAG — the penultimate intermediate in triglyceride synthesis — is highly correlated with Hep-IR in rats, mice and humans 44,59–61 .”
Helsley, R. N., Varadharajan, V., Brown, A. L., Gromovsky, A. D., Schugar, R. C., Ramachandiran, I., Fung, K., Kabbany, M. N., Banerjee, R., Neumann, C. K. A., et al. (2019) · eLife · doi:10.7554/elife.49882 · Cited by 129
An integrative systems genetic analysis of mammalian lipid metabolism
Parker, B. L., Calkin, A. C., Seldin, M. M., Keating, M. F., Tarling, E. J., Yang, P., Moody, S. C., Liu, Y., Zerenturk, E. J., Needham, E. J., et al. (2019) · Nature · doi:10.1038/s41586-019-0984-y · Cited by 127
Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
Finck, B. N. (2018) · Diabetes · doi:10.2337/dbi18-0024 · Cited by 125
“For example, diacylglycerol, the penultimate intermediate in the triglyceride synthesis pathways, and ceramide, a complex membrane lipid, have been shown to inhibit insulin signaling at the insulin receptor or proximal mediators (6,7).”
BackgroundEmerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease
Chen, Z., Yu, Y., Cai, J., & Li, H. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.08.006 · Cited by 127
Mingrone, G., van Baar, A. C., Devière, J., Hopkins, D., Moura, E., Cercato, C., Rajagopalan, H., Lopez-Talavera, J. C., White, K., Bhambhani, V., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-323608 · Cited by 120
Most, J., Gilmore, L. A., Smith, S. R., Han, H., Ravussin, E., & Redman, L. M. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00261.2017 · Cited by 117
Jyotsna, F., Ahmed, A., Kumar, K., Kaur, P., Chaudhary, M. H., Kumar, S., Khan, E. A., Khanam, B., Shah, S. U., Varrassi, G., et al. (2023) · Cureus · doi:10.7759/cureus.43882 · Cited by 143
“For example, it has been demonstrated that GLP-1 receptor agonists and SGLT-2 inhibitors, in addition to their ability to lower glucose levels, have the potential to enhance atherogenic dyslipidemia and decrease cardiovascular events in individuals diagnosed with type 2 diabetes [9,10].”
BackgroundZhao, Z., Wang, Z., Zhou, D., Han, Y., Ma, F., Hu, Z., Xin, F., Liu, X., Ren, T., Zhang, F., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.05.006 · Cited by 113
“(Cell Mol Gastroenterol Hepatol 2021;12:857–871; https://doi.org/ 10.1016/j.jcmgh.2021.05.006) Keywords: Sodium Butyrate; Insulin-Induced Gene; LKB1; Hepatic Lipogenesis; NAFLD. epatic steatosis is a major characteristic of nonal- *Authors share co-first authorship Abbreviations used in this paper: ACC, acetyl-CoA car…”
BackgroundInfluentialYang, J., Chen, H., Nie, Q., Huang, X., & Nie, S. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.08.007 · Cited by 109
The mTORC2 signaling network: targets and cross-talks
Ragupathi, A., Kim, C., & Jacinto, E. (2024) · Biochemical Journal · doi:10.1042/bcj20220325 · Cited by 122
Teng, W., Zhao, L., Yang, S., Zhang, C., Liu, M., Luo, J., Jin, J., Zhang, M., Bao, C., Li, D., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.023 · Cited by 107
Lv, T., Fan, X., He, C., Zhu, S., Xiong, X., Yan, W., Liu, M., Xu, H., Shi, R., & He, Q. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103159 · Cited by 114
“Yet in NASH, mitochondrial adaptations are completely lost, and a low respiration rate and increased mitochondrial mass were observed [11, 12].”
BackgroundRole of Oxidative Stress in Liver Disorders
Conde de la Rosa, L., Goicoechea, L., Torres, S., Garcia-Ruiz, C., & Fernandez-Checa, J. C. (2022) · Livers · doi:10.3390/livers2040023 · Cited by 107
“In the liver, the metabolism of lipids is regulated by nuclear receptors that activate diverse ligands and modulate important enzymes involved in lipogenesis and lipoxidation [181], acting as redox triggers that in turn affect several metabolic pathways due to particular ROS [182].”
BackgroundWang, H., Cao, Y., Shu, L., Zhu, Y., Peng, Q., Ran, L., Wu, J., Luo, Y., Zuo, G., Luo, J., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14818 · Cited by 105
Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi
Xiong, X., Wang, Q., Wang, S., Zhang, J., Liu, T., Guo, L., Yu, Y., & Lin, J. D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.004 · Cited by 100
FGF21 regulates hepatic metabolic pathways to improve steatosis and inflammation
Keinicke, H., Sun, G., Mentzel, C. M. J., Fredholm, M., John, L. M., Andersen, B., Raun, K., & Gerstenberg, M. K. (2020) · Endocrine Connections · doi:10.1530/ec-20-0152 · Cited by 104
“support that FGF21 independent of weight loss protected the liver against inflammation and inflammatory processes (25, 68-70) An important question is whether the findings in the DIO mice can be translated into humans.”
BackgroundLipophagy: Molecular Mechanisms and Implications in Metabolic Disorders.
Shin, D. W. (2020) · PubMed Central · doi:10.14348/molcells.2020.0046 · Cited by 105
“NAFLD exhibits insulin resistance and lipogenesis (Samuel and Shulman, 2018; Tavernarakis et al., 2019).”
Sonavane, M., & Gassman, N. R. (2019) · Critical Reviews in Toxicology · doi:10.1080/10408444.2019.1621263 · Cited by 103
“…and insulin sensitivity by combined exposure to BPA and arsenic may be due to the upregulation of enzymes or genes involved in gluconeogenesis (Gys2) and glucose uptake (Glut2), as insulin is known to activate glucose transport and gluconeogenesis in skeletal muscle (Samuel and Shulman 2018).”
BackgroundThe Role of microRNAs in Metabolic Syndrome-Related Oxidative Stress
Włodarski, A., Strycharz, J., Wróblewski, A. M., Kasznicki, J., Drzewoski, J., & Śliwińska, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186902 · Cited by 99
The pathophysiology of MASLD: an immunometabolic perspective
Schwärzler, J., Grabherr, F., Grander, C., Adolph, T. E., & Tilg, H. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2294046 · Cited by 107
“Accumulation of liver fat is considered as an early step in the origin of the disease and is frequently observed in patients with type 2 diabetes or obesity [21].”
Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
Lim, S. K., Taskinen, M., & Borén, J. (2018) · Obesity Reviews · doi:10.1111/obr.12820 · Cited by 99
“Thus, NAFLD is emerging as a component of cardiometabolic syndrome based on hepatic and peripheral insulin resistance.(83,90) Taken together, these findings suggest that fat accumulation in the liver is a critical determinant of metabolic flux and inflammatory processes, thereby representing an important therapeutic t…”
BackgroundRen, H., Hu, F., Wang, D., Kang, X., Feng, X., Zhang, L., Zhou, B., Liu, S., & Yuan, G. (2021) · Hepatology · doi:10.1002/hep.31773 · Cited by 95
Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma
Fan, Y., Chan, M. S. M., & Lee, T. K. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.01.006 · Cited by 101
Hepatic ketogenic insufficiency reprograms hepatic glycogen metabolism and the lipidome
d’Avignon, D. A., Puchalska, P., Erçal, B., Chang, Y., Martin, S. E., Graham, M. J., Patti, G. J., Han, X., & Crawford, P. A. (2018) · JCI Insight · doi:10.1172/jci.insight.99762 · Cited by 89
Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides
Samuel, V. T., & Shulman, G. I. (2019) · New England Journal of Medicine · doi:10.1056/nejmcibr1910023 · Cited by 90
Self-citationHu, P., Li, K., Peng, X., Kan, Y., Li, H., Zhu, Y., Wang, Z., Li, Z., Liu, H., & Cai, D. (2023) · Nutrients · doi:10.3390/nu15224772 · Cited by 91
“It is characterized by the accumulation of neutral lipids forming lipid droplets in liver cells [18].”
BackgroundSignaling pathways and intervention for therapy of type 2 diabetes mellitus
Cao, R. Y., Tian, H., Zhang, Y., Liu, G., Xu, H., Rao, G., Tian, Y., & Fu, X. (2023) · MedComm · doi:10.1002/mco2.283 · Cited by 98
Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease
Akhtar, D. H., Iqbal, U., Vazquez‐Montesino, L. M., Dennis, B. B., & Ahmed, A. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00028 · Cited by 89
“These studies did not demonstrate any association between insulin sensitivity and other factors implicated in hepatic insulin resistance, such as ceramide content, endoplasmic reticulum stress markers, or inflammatory cytokine concentrations.60–63 Studies with mice lacking glycogen synthase demonstrate increased lipog…”
BackgroundInfluentialEndocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease
Treviño, L. S., & Katz, T. A. (2017) · Endocrinology · doi:10.1210/en.2017-00887 · Cited by 88
Baicalin and its aglycone: a novel approach for treatment of metabolic disorders
Fang, P., Yu, M., Shi, M., Bo, P., Gu, X., & Zhang, Z. (2020) · Pharmacological Reports · doi:10.1007/s43440-019-00024-x · Cited by 83
“Only a small proportion of subjects with NAFLD develop NASH and subsequently liver fibrosis, cirrhosis and hepatocellular carcinoma, while most of them only exhibit simple steatosis [41, 42].”
BackgroundApplications of human organoids in the personalized treatment for digestive diseases
Wang, Q., Guo, F., Jin, Y., & Ma, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01194-6 · Cited by 87
“Fatty liver disease is attributed to a variety of causes, including an obese diet, a sedentary lifestyle, and the prevalence of metabolic disorders.(183,184) Human hepatocyte-differentiated organoids and liver-derived intrahepatic cholangiocyte organoids can recapitulate some pathologies of fatty liver disease, such a…”
BackgroundAdvances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Yin, X., Guo, X., Liu, Z., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032844 · Cited by 86
“Fatty acid synthase (FAS) catalyzes palmitic acid generation from malo- nyl-CoA and acetyl-CoA.”
BackgroundInfluentialEffects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans
Borén, J., Adiels, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J., Ståhlman, M., Ripatti, P., Ripatti, S., Palotie, A., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.144079 · Cited by 81
Goedeke, L., Perry, R. J., & Shulman, G. I. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104727 · Cited by 76
“While several diabetes medications have also been studied as potential treatments for nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of insulin resistance, we refer readers to two recent reviews that discuss this in greater detail [by Samuel & Shulman (24) and Alkhouri et al.”
BackgroundInfluentialSelf-citationSteatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 79
Zhou, L., Qiu, X., Meng, Z., Liu, T., Chen, Z., Zhang, P., Kuang, H., Pan, T., Lu, Y., Qi, L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk1866 · Cited by 85
“Hepatic steatosis results from derangements of hepatic lipid metabolism and is exacerbated by insulin resistance and adipose tissue dysfunction ( 5 , 6 ).”
BackgroundSun, R., Xu, D., Wei, Q., Zhang, B., Aa, J., Wang, G., & Xie, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109721 · Cited by 75
Evaluating causality of cellular senescence in non-alcoholic fatty liver disease
Meijnikman, A. S., Herrema, H., Scheithauer, T. P. M., Kroon, J., Nieuwdorp, M., & Groen, A. K. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100301 · Cited by 81
“However, high levels of FFAs, free cholesterol and other lipid metabolites can lead to lipotoxicity.(14) Lipotoxicity causes mitochondrial dysfunction, resulting in the formation of reactive oxygen species (ROS), endoplasmic reticulum (ER) stress, inflammation and cell damage(14,22) As a consequence of the overload of…”
BackgroundSingle-nucleus RNA-seq2 reveals functional crosstalk between liver zonation and ploidy
Richter, M. L., Deligiannis, I. K., Yin, K., Danese, A., Lleshi, E., Coupland, P., Vallejos, C. A., Matchett, K. P., Henderson, N. C., Colome-Tatche, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24543-5 · Cited by 75
Dallio, M., Sangineto, M., Romeo, M., Villani, R., Romano, A. D., Loguercio, C., Serviddio, G., & Federico, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010436 · Cited by 77
Stols‐Gonçalves, D., Mak, A. L., Madsen, M. S. A., van der Vossen, E. W. J., Bruinstroop, E., Henneman, P., Mol, F., Scheithauer, T. P. M., Smits, L. P., Witjes, J. J., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2223330 · Cited by 72
“45 In NAFLD, adipose tissue insulin resistance increases lipolysis and the glycerol flux to the liver, increasing hepatic gluconeogenesis.”
BackgroundNachit, M., & Leclercq, I. A. (2019) · Clinical Science · doi:10.1042/cs20180421 · Cited by 75
Wang, Z., Zhu, S., Jia, Y., Wang, Y., Kubota, N., Fujiwara, N., Gordillo, R., Lewis, C., Zhu, M., Sharma, T., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.014 · Cited by 72
Metadata
- Authors
- Samuel, V. T., & Shulman, G. I.
- Affiliations
- United States Department of Veterans Affairs (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Samuel, Varman T.
- Shulman, Gerald I.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 27
- Issue
- 1
- Pages
- 22-41
- ISSN
- 1550-4131 (ISSN-L)
- PMC
- PMC5762395
- OpenAlex
- W2752428556
- Cited by
- 745
- References
- 263
- Citations by year
- 2026: 72 · 2025: 84 · 2024: 90 · 2023: 109 · 2022: 88 · 2021: 91 · 2020: 81 · 2019: 71 · 2018: 50
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Celgene
- Novo Nordisk
- National Institutes of Health (DK-40936, DK-45735, DK-R01 DK 11398401)
- AstraZeneca
- Gilead Sciences
- Merck
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, hepatic insulin resistance, diacylglycerol, protein kinase C epsilon, insulin receptor, glycogen synthesis, lipogenesis, gluconeogenesis, pyruvate carboxylase, bariatric surgery, weight loss, PPAR agonists, farnesoid X receptor, FGF21, glucagon-like peptide-1, acetyl-CoA carboxylase, stearoyl-CoA desaturase, mitochondrial uncoupling, therapeutic target
- MeSH terms
- Animals, Glucose, Humans, Insulin, Insulin Resistance, Metabolic Diseases, Lipid Metabolism, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
